On Oct. 7, 2021, PerkinElmer announced that the U.S. Food and Drug Administration (FDA) had issued Emergency Use Authorization (EUA) for the PKampﾙ Respiratory SARS-CoV-2 RT-PCR Panel 1 assay.

Qualified laboratories can immediately use this single test for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) isolated from nasopharyngeal swabs, anterior nasal swabs and mid-turbinate swabs.